GleamWall
中文EN

RCKT ROCKET PHARMACEUTICALS, INC.

Pharmaceutical Preparations · Nasdaq · SEC CIK 1281895 · Fiscal year ends 12/31

Financial factors as of 2026-09-30 (2026Q3), TTM = sum of the last four quarters

Growth

TTM revenue YoY—
TTM net income YoY93.3%
TTM EPS YoY93.3%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—

Margins

Gross margin—
Operating margin—
Net margin—
FCF margin—
EBITDA margin—

Returns

ROE-5.0%
ROA-4.1%
ROIC (approx.)-60.4%
Asset turnover0.00x

Leverage & solvency

Liabilities / assets22.1%
Debt / equity0.09x
Current ratio7.26x
Interest coverage-100.61x

Cash quality & payout

Operating cash flow / net income9.84x
Accruals ratio36.3%
Payout ratio—
Capex / revenue—

Factor history charts and full statement history on Pro 🔒

Financial statements

Line item 2026Q32026-09-302026Q22026-06-302026Q12026-03-312025Q4*2025-12-312025Q32025-09-302025Q22025-06-302025Q12025-03-312024Q4*2024-12-31
Income statement
Revenue$0$0$0$0$0$0$0$0
R&D expense$31.17M$29.50M$31.45M$29.35M$34.07M$42.66M$35.94M$37.36M
SG&A expense$19.79M$17.43M$17.06M$14.68M$18.35M$25.02M$28.45M$25.34M
Operating income-$50.97M-$46.92M-$48.51M-$43.96M-$52.25M-$71.15M-$64.39M-$62.69M
Interest expense$473,000$473,000$473,000$473,000$473,000$473,000$472,000$473,000
Pretax income-$49.18M$131.84M—-$42.54M-$50.33M-$68.92M——
Income tax$54,000$8.62M—$0$0$0——
Net income-$49.23M$123.21M-$47.59M-$42.54M-$50.33M-$68.92M-$61.33M-$60.33M
EBITDA-$49.47M-$45.32M-$46.91M-$42.26M-$49.55M-$69.15M-$61.89M-$60.89M
EPS (basic)-0.431.09-0.42—-0.45-0.62-0.56—
EPS (diluted)-0.431.08-0.42—-0.45-0.62-0.56—
Weighted avg. shares (diluted)113.65M114.51M112.13M—111.57M111.02M110.09M—
Balance sheet
Cash & equivalents$95.47M$224.51M$49.61M$77.56M$77.31M$34.18M$51.17M$165.00M
Short-term investments$174.04M$59.24M$94.77M$111.37M$146.81M$238.68M$268.35M$208.70M
Inventory$393,000——$0————
Current assets$278.05M$289.55M$149.83M$192.73M$227.68M$277.15M$324.49M$378.18M
PP&E, net$23.76M$25.10M$26.66M$28.17M$29.77M$32.52M$34.56M$36.79M
Goodwill$39.15M$39.15M$39.15M$39.15M$39.15M$39.15M$39.15M$39.15M
Intangibles$25.15M$25.15M$25.15M$25.15M$25.15M$25.15M$25.15M$25.15M
Total assets$419.50M$423.10M$285.41M$330.45M$368.03M$420.98M$471.07M$527.70M
Current liabilities$38.32M$31.32M$24.47M$30.21M$31.17M$43.40M$35.31M$40.68M
Short-term debt$0———————
Long-term debt$30.43M——$0————
Total debt$30.43M——$0————
Total liabilities$92.78M$54.27M$47.37M$53.23M$54.36M$66.77M$58.93M$64.47M
Shareholders' equity$326.72M$368.83M$238.04M$277.22M$313.67M$354.21M$412.14M$463.23M
Net debt-$65.04M——-$77.56M————
Shares outstanding111.39M109.54M109.12M108.32M108.21M107.88M106.75M106.45M
Cash flow statement
Operating cash flow-$39.05M-$39.61M-$45.39M-$34.84M-$50.42M-$48.96M-$55.79M-$46.94M
Capital expenditure$151,000$8,000$93,000$80,000-$54,000$50,000$364,000$309,000
Free cash flow-$39.20M-$39.62M-$45.49M-$34.92M-$50.37M-$49.01M-$56.15M-$47.25M
Investing cash flow-$124.02M$214.36M$17.45M$36.42M$93.62M$31.76M-$58.03M-$37.87M
Financing cash flow$34.03M$150,000-$1,000$0-$67,000$215,000$0$182.85M
Depreciation & amortization$1.50M$1.60M$1.60M$1.70M$2.70M$2.00M$2.50M$1.80M
Stock-based compensation$7.35M$7.42M$8.49M$6.11M$9.76M$10.86M$10.33M$11.09M

Free plan shows the latest 8 periods; Pro shows all 51 🔒

· This company does not report gross profit in XBRL.

· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.

· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.

Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-21 06:27.